InjectionClinical Overview
Hydroxyprogesterone Caproate Injection IP (250mg, 500mg) is a long-acting synthetic esterified progestogen formulated in an oily depot solution. It binds to uterine progesterone receptors, producing prolonged quietening of the myometrium, inhibiting cervical shortening, and suppressing inflammatory cytokine-mediated uterine contractility. Indicated for the prevention of recurrent preterm birth in pregnant women with a singleton pregnancy and a documented history of spontaneous preterm singleton delivery, habitual/threatened miscarriage, and uterine bleeding disorders.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
For Deep Intramuscular (IM) injection ONLY: 250 mg to 500 mg administered deep into the upper outer quadrant of the gluteal muscle once weekly by a healthcare professional. For preterm labor prophylaxis: initiate between 16 weeks 0 days and 20 weeks 6 days of gestation and continue weekly until 36 weeks 6 days or delivery. Warm ampoule between hands prior to aspiration; inject slowly with a 21G needle. NEVER administer intravenously.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Injection site reactions (pain, swelling, pruritus, nodule formation, bruising), urticaria, nausea, headache, and diarrhea. Rare/Severe: Thromboembolism, gestational diabetes, hypertension, and severe allergic reactions.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in current or history of thrombosis or thromboembolic disorders, known or suspected breast or hormone-sensitive cancer, undiagnosed abnormal vaginal bleeding, cholestatic jaundice of pregnancy, and severe liver disease. Monitor for signs of gestational diabetes and thromboembolism.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Gynecological, Obstetric & Endocrinological Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice or reproductive healthcare guidance. Hormonal medications, uterotonics, corticosteroids, fertility therapies, and emergency contraceptives have profound systemic actions and must be administered strictly under the supervision of a registered gynecologist, obstetrician, or endocrinologist.